These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 15708355

  • 1. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation.
    Planavila A, Laguna JC, Vázquez-Carrera M.
    Biochim Biophys Acta; 2005 Feb 21; 1687(1-3):76-83. PubMed ID: 15708355
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells.
    Planavila A, Sánchez RM, Merlos M, Laguna JC, Vázquez-Carrera M.
    Biochim Biophys Acta; 2005 Sep 15; 1736(2):120-7. PubMed ID: 16139565
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.
    Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M.
    Cardiovasc Res; 2005 Mar 01; 65(4):832-41. PubMed ID: 15721863
    [Abstract] [Full Text] [Related]

  • 4. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy.
    Planavila A, Laguna JC, Vázquez-Carrera M.
    J Biol Chem; 2005 Apr 29; 280(17):17464-71. PubMed ID: 15728586
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli.
    Planavila A, Rodríguez-Calvo R, Palomer X, Coll T, Sánchez RM, Merlos M, Laguna JC, Vázquez-Carrera M.
    Biochim Biophys Acta; 2008 Apr 29; 1781(1-2):26-35. PubMed ID: 18036354
    [Abstract] [Full Text] [Related]

  • 7. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
    Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, Hernández G, Egido J.
    J Am Coll Cardiol; 1998 Dec 29; 32(7):2057-64. PubMed ID: 9857893
    [Abstract] [Full Text] [Related]

  • 8. Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
    Lu JC, Cui W, Zhang HL, Liu F, Han M, Liu DM, Yin HN, Zhang K, Du J.
    Clin Exp Pharmacol Physiol; 2009 Nov 29; 36(11):1110-9. PubMed ID: 19413592
    [Abstract] [Full Text] [Related]

  • 9. [Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro].
    Sheng L, Ye P, Liu YX.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec 29; 33(12):1080-4. PubMed ID: 16563274
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo.
    Ye P, Sheng L, Zhang C, Liu Y.
    J Pharm Pharm Sci; 2006 Dec 29; 9(3):365-75. PubMed ID: 17207419
    [Abstract] [Full Text] [Related]

  • 11. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
    Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK.
    J Clin Endocrinol Metab; 2011 Sep 29; 96(9):2889-97. PubMed ID: 21752880
    [Abstract] [Full Text] [Related]

  • 12. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
    Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I.
    J Am Coll Cardiol; 2004 Apr 21; 43(8):1481-8. PubMed ID: 15093887
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway.
    Yang J, Huang C, Yang J, Jiang H, Ding J.
    Mol Cell Biochem; 2010 Dec 21; 345(1-2):189-95. PubMed ID: 20714791
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
    Zou J, Le K, Xu S, Chen J, Liu Z, Chao X, Geng B, Luo J, Zeng S, Ye J, Liu P.
    Mol Cell Endocrinol; 2013 May 06; 370(1-2):103-12. PubMed ID: 23518069
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine.
    Yin Z, Fang Y, Ren L, Wang X, Zhang A, Lin J, Li X.
    Neurosci Lett; 2009 Nov 06; 465(1):61-5. PubMed ID: 19733216
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
    Vilà L, Rebollo A, Ađalsteisson GS, Alegret M, Merlos M, Roglans N, Laguna JC.
    Toxicol Appl Pharmacol; 2011 Feb 15; 251(1):32-40. PubMed ID: 21122807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.